三重阴性乳腺癌中的免疫疗法耐药性:分子机制,瘤微环境和治疗影响
1School of Medicine, Jiangsu University, Zhenjiang, China.
Frontiers in oncology
|September 12, 2025
概括
三重阴性乳腺癌 (TNBC) 由于其高免疫性和淋巴细胞透,对免疫治疗有希望. 本综述探讨了TNBC中免疫检查点抑制剂治疗的耐药性机制和临床策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 三重阴性乳腺癌 (TNBC) 是具有攻击性,侵入性和转移性的,由于缺乏ER,PR和HER2,治疗选择有限.
- 在TNBC中转移和耐药性涉及复杂的分子和信号通路.
- 免疫疗法,特别是免疫检查点抑制剂 (ICI),为TNBC治疗提供了新的希望.
研究的目的:
- 审查了解TNBC免疫疗法耐药性的最新进展.
- 探索分子机制,遗传因素以及瘤微环境在TNBC耐药性中的作用.
- 为克服ICI耐药性在新辅助TNBC治疗中的临床策略提供见解.
主要方法:
- 关于TNBC免疫疗法的最新进展的文献综述.
- 对参与抗性的分子机制,基因和途径的分析.
- 检查瘤微环境对治疗疗效的影响.
主要成果:
- 与其他亚型相比,TNBC具有更高的免疫性,新抗原负载和瘤透淋巴细胞 (TIL).
- 在TNBC中更高的PD-L1表达与TIL丰度相关,支持ICI治疗.
- 临床试验显示,ICI在TNBC中具有有希望的疗效,挑战了以前对乳腺癌免疫疗法不敏感的观念.
结论:
- TNBC的独特特性使其成为免疫治疗的强有力的候选者.
- 了解耐药机制对于优化TNBC中的ICI治疗至关重要.
- 需要进一步的研究和临床策略来改善接受新辅助ICI治疗TNBC的患者的治疗结果.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
3.8K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
11.1K
相关概念视频
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
